<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01878890</url>
  </required_header>
  <id_info>
    <org_study_id>IB2011-01</org_study_id>
    <nct_id>NCT01878890</nct_id>
  </id_info>
  <brief_title>Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.</brief_title>
  <acronym>ESCALE</acronym>
  <official_title>Phase I Dose Escalation Trial of Efavirenz for Patients With Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Bergonié</source>
  <brief_summary>
    <textblock>
      Hypothesis: encouraging results of phase II study FAVE in the treatment of hormonal resistant&#xD;
      prostate cancer lead us to continue clinical development of efavirenz. Furthermore, all&#xD;
      available pre-clinical and clinical data lead us to conduct a Phase 1 study with efavirenz.&#xD;
      Objective of this Phase I is to test doses above 600 mg / day in patients with cancer in&#xD;
      order to determine the maximum tolerated dose to improve therapeutic effect.&#xD;
&#xD;
      This study is a single center Phase I trial, conduct with dose escalation scheme of efavirenz&#xD;
      by continual reassessment method likehood approach (CRML) on solid tumours (except pancreatic&#xD;
      cancer) and non-Hodgkin lymphoma (NHL).&#xD;
&#xD;
      Main objective is to determine the safety profile, and particularly the maximum tolerated&#xD;
      dose of efavirenz for the treatment of patients with solid tumors (except pancreatic cancer)&#xD;
      or NHL in therapeutic failure.&#xD;
&#xD;
      Secondary objectives are:&#xD;
&#xD;
        -  Evaluate efavirenz pharmacokinetics at 2, 4 and 12 weeks;&#xD;
&#xD;
        -  Evaluate objective response at 12 weeks;&#xD;
&#xD;
        -  Evaluate progression free survival at 6 months;&#xD;
&#xD;
        -  Assess biological progression-free survival at 6 months (prostate tumours only).&#xD;
&#xD;
      Primary Endpoint&#xD;
&#xD;
      Safety will be evaluated according to the toxicity scale NCI-CTCAE v4.0. Dose limiting&#xD;
      toxicities will be collected during the first 28 days (+ / - 7 days) after first dose of&#xD;
      Efavirenz and will be defined as follows:&#xD;
&#xD;
        -  Any drug-related toxicity with grade ≥ 3 according to NCI-CTCAE v4.0 (except alopecia,&#xD;
           nausea and vomiting, regardless of grade),&#xD;
&#xD;
        -  Any drug-related toxicity, regardless of grade, who led a treatment delay&gt; 14 days,&#xD;
&#xD;
        -  Score ≥ 19 HAD during treatment. Secondary Criteria&#xD;
&#xD;
        -  Solid tumors: response and progression defined by RECIST v1.1 [Eisenhauer EA et al. EJC&#xD;
           2009).&#xD;
&#xD;
        -  Non-Hodgkin lymphomas: Response and progression defined according to Cheson criteria&#xD;
           [Cheson BD et al. JCO 1999]&#xD;
&#xD;
        -  Biological progression (particular case of prostate tumors): defined according to Scher&#xD;
           [Scher HI et al. JCO 2008] Statistical Considerations This is a Phase I dose escalation&#xD;
           strategy using the method CRML, described by O'Quigley and Shen [O'Quigley et al.&#xD;
           Biometrics 1996] and commonly used in Phase I trials in oncology.&#xD;
&#xD;
        -  Maximum number of eligible and evaluable subjects is 30.&#xD;
&#xD;
        -  Six dose levels are initially defined: 600 mg, 1200 mg, 1800 mg, 2200 mg, 2600 mg, 3000&#xD;
           mg.&#xD;
&#xD;
        -  The risk of dose limiting toxicities maximum allowed is 25%.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I dose escalation strategy according to the method described by CRML&#xD;
      O'Quigley and Shen [O'Quigley et al. Biometrics 1996] and commonly used in phase I trials in&#xD;
      oncology.&#xD;
&#xD;
      Six levels of doses are initially defined: 600 mg, 1200 mg, 1800 mg, 2200 mg, 2600 mg, 3000&#xD;
      mg.&#xD;
&#xD;
      The maximum potential dose-limiting toxicities allowed is 25%.&#xD;
&#xD;
      Dose limiting toxicities will be defined as follows:&#xD;
&#xD;
        -  Any drug-related toxicity with grade ≥ 3 according to NCI-CTCAE v4.0 (except alopecia,&#xD;
           nausea and vomiting, regardless of grade),&#xD;
&#xD;
        -  Any drug-related toxicity, regardless of grade, who led a treatment delay&gt; 14 days,&#xD;
&#xD;
        -  Score ≥ 19 HAD during treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2011</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">September 16, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Efavirenz</measure>
    <time_frame>Up to 28 days for each dosing cohort</time_frame>
    <description>MTD was determined by testing increasing doses up to 3000 mg (oral daily intake).&#xD;
The dose escalation scheme is the continual reassessment method likehood approach (CRML) described by O'Quigley and Shen [O'Quigley et al. Biometrics 1996].&#xD;
MTD reflects the highest dose of drug that did not cause a Dose-Limiting Toxicity (DLT) in &gt; 25% of participants.&#xD;
A DLT was any drug-related toxicity with grade ≥ 3 according to NCI-CTCAE v4.0 (except alopecia, nausea and vomiting, regardless of grade), any drug-related toxicity, regardless of grade, who led a treatment delay&gt; 14 days, a score ≥ 19 for the Hospital Anxiety And Depression Scale (HAD) during treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 28 days for each dosing cohort</time_frame>
    <description>A DLT was any drug-related toxicity with grade ≥ 3 according to NCI-CTCAE v4.0 (except alopecia, nausea and vomiting, regardless of grade), any drug-related toxicity, regardless of grade, who led a treatment delay&gt; 14 days, a score ≥ 19 for the Hospital Anxiety And Depression Scale (HAD) during treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>12-week Objective Response Rate</measure>
    <time_frame>up to 3 months after first adminitration of Efavirenz</time_frame>
    <description>Objective response is defined as complete or partial response (CR, PR) using the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Objective reponse rate is calculated as the number of patients with objective reponse divided by the number of alive patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-week Non-progression Rate</measure>
    <time_frame>Evaluated up to 3 months after first administration of Efavirenz</time_frame>
    <description>Non progression is defined as complete or partial response (CR, PR) or stable disease (SD), using the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Non-progression rate is calculated as the number of alive and progression free patients divided by the number of patients.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Efavirenz: 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 : Participants received 600 mg of Efavirenz (oral / once a day), until progression or toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavirenz: 1200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 : Participants received 1200 mg of Efavirenz (oral / once a day), until progression or toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavirenz: 1800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3 : Participants received 1800 mg of Efavirenz (oral / once a day), until progression or toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavirenz: 2200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4 : Participants received 2200 mg of Efavirenz (oral / once a day), until progression or toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz 600mg</intervention_name>
    <description>Efavirenz 600 mg (oral daily intake)</description>
    <arm_group_label>Efavirenz: 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz 1200 mg</intervention_name>
    <description>Efavirenz 1200mg (oral daily intake)</description>
    <arm_group_label>Efavirenz: 1200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz 1800 mg</intervention_name>
    <description>Efavirenz 1800mg (oral daily intake)</description>
    <arm_group_label>Efavirenz: 1800 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz 2200 mg</intervention_name>
    <description>Efavirenz 2200mg (oral daily intake)</description>
    <arm_group_label>Efavirenz: 2200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          1. Patients with solid tumors (except pancreatic cancer) or non-Hodgkin lymphoma&#xD;
&#xD;
          2. Metastatic disease or locally advanced inoperable tumor, not accessible to standard&#xD;
             therapy.&#xD;
&#xD;
          3. Male or female ≥ 18 years and &lt;80 years.&#xD;
&#xD;
          4. Tumor assessable by RECIST v1.1, Scher Cheson 2008 or 99.&#xD;
&#xD;
          5. At least 28 days after completion of prior treatment (radiotherapy, systemic&#xD;
             chemotherapy or major surgery).&#xD;
&#xD;
          6. Patient who recovered from any prior toxicity ≤ grade 1.&#xD;
&#xD;
          7. WHO 0-1 in the 7 days before inclusion.&#xD;
&#xD;
          8. Neutrophils ≥ 1500/mm3, Platelets ≥ 100 000/mm3.&#xD;
&#xD;
          9. Total bilirubin and serum creatinine within normal limits (≤ 1.5 ULN), creatinine&#xD;
             clearance ≥ 40 ml / min.&#xD;
&#xD;
         10. AST / ALT ≤ 1.5 ULN (≤ 5 ULN if liver metastasis).&#xD;
&#xD;
         11. Normal thyroid function.&#xD;
&#xD;
         12. Normal coagulation: TP ≥ 70%.&#xD;
&#xD;
         13. Life expectancy upper than 3 months.&#xD;
&#xD;
         14. HAD score &lt;13.&#xD;
&#xD;
         15. Negative pregnancy test for women likely to be pregnant within 7 days before&#xD;
             inclusion.&#xD;
&#xD;
         16. Effective contraception for the duration of treatment (for both sexes in childbearing&#xD;
             or reproductive age): mechanic contraception method should always be used in&#xD;
             combination with other contraceptive methods (eg, oral or other hormonal&#xD;
             contraceptives). Because of long half-life of efavirenz, it is recommended to use&#xD;
             adequate contraceptive measures for 12 weeks after stopping treatment with efavirenz.&#xD;
&#xD;
         17. Informed consent signed and dated by the patient or his legal representative before&#xD;
             the establishment of any specific procedure to the study.&#xD;
&#xD;
         18. Clinical examination and laboratory tests made within 7 days before enrollment and&#xD;
             start of treatment.&#xD;
&#xD;
         19. Initial assessment and radiological CT / or MRI performed within 30 days before&#xD;
             enrollment.&#xD;
&#xD;
         20. Patients potentially compliant with treatment and follow-up study.&#xD;
&#xD;
         21. Ability to swallow capsules or tablets.&#xD;
&#xD;
         22. Patients insured by a social security system.&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          1. Patient with pancreatic cancer.&#xD;
&#xD;
          2. Presence of active or symptomatic cerebral localization (known).&#xD;
&#xD;
          3. History of another cancer except:&#xD;
&#xD;
               -  cancer occurred more than five years and considered in complete remission&#xD;
&#xD;
               -  in situ cervix carcinomas,&#xD;
&#xD;
               -  cutaneous basal cell carcinomas.&#xD;
&#xD;
          4. Current major depressive state (screening by HAD scale total score ≥ 13).&#xD;
&#xD;
          5. Patients with history of depressive disorders, suicide attempts, addiction or other&#xD;
             psychiatric disorders.&#xD;
&#xD;
          6. Concomitant use of terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide,&#xD;
             bepridil, alkaloids of ergot, voriconazole, mixing St. John's Wort.&#xD;
&#xD;
          7. Patients treated with anti-vitamin K. Treatment with low molecular weight heparin are&#xD;
             allowed.&#xD;
&#xD;
          8. Known efavirenz hypersensitivity or to any of its excipients.&#xD;
&#xD;
          9. Severe renal impairment.&#xD;
&#xD;
         10. Severe hepatic impairment.&#xD;
&#xD;
         11. Yellow fever vaccine (yellow fever).&#xD;
&#xD;
         12. Pregnant or lactating.&#xD;
&#xD;
         13. Presence of toxicity&gt; 1 according to the criteria CTCAE V4.0, due to prior cancer&#xD;
             therapy.&#xD;
&#xD;
         14. Recurrent diarrhea which can interfere with drug absorption capacity.&#xD;
&#xD;
         15. Patient included in another biomedical research on a drug within 30 days of inclusion.&#xD;
&#xD;
         16. Patient who previously participated in this study.&#xD;
&#xD;
         17. Patient, who for reasons psychological, psychiatric, social, family or geographical&#xD;
             could not be treated or monitored regularly by the criteria of the study, patients&#xD;
             deprived of liberty or under tutorship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guilhem Roubaud, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 29, 2012</study_first_submitted>
  <study_first_submitted_qc>June 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2013</study_first_posted>
  <results_first_submitted>November 26, 2020</results_first_submitted>
  <results_first_submitted_qc>January 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2021</results_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumors (other than pancreas)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Efavirenz - 600 mg</title>
          <description>Participants received 600 mg of Efavirenz (oral / once a day), until progression or toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Efavirenz - 1200 mg</title>
          <description>Participants received 1200 mg of Efavirenz (oral / once a day), until progression or toxicity.</description>
        </group>
        <group group_id="P3">
          <title>Efavirenz - 1800 mg</title>
          <description>Participants received 1800 mg of Efavirenz (oral / once a day), until progression or toxicity.</description>
        </group>
        <group group_id="P4">
          <title>Efavirenz - 2200 mg</title>
          <description>Participants received 2200 mg of Efavirenz (oral / once a day), until progression or toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Efavirenz: 600 mg</title>
          <description>Cohort 1 : Participants received 600 mg of Efavirenz (oral / once a day), until progression or toxicity.&#xD;
Efavirenz 600mg: Efavirenz 600 mg (oral daily intake)</description>
        </group>
        <group group_id="B2">
          <title>Efavirenz: 1200 mg</title>
          <description>Cohort 2 : Participants received 1200 mg of Efavirenz (oral / once a day), until progression or toxicity.&#xD;
Efavirenz 600mg: Efavirenz 1200 mg (oral daily intake)</description>
        </group>
        <group group_id="B3">
          <title>Efavirenz: 1800 mg</title>
          <description>Cohort 3 : Participants received 1800 mg of Efavirenz (oral / once a day), until progression or toxicity.&#xD;
Efavirenz 600mg: Efavirenz 1800 mg (oral daily intake)</description>
        </group>
        <group group_id="B4">
          <title>Efavirenz: 2200 mg</title>
          <description>Cohort 4 : Participants received 2200 mg of Efavirenz (oral / once a day), until progression or toxicity.&#xD;
Efavirenz 600mg: Efavirenz 2200 mg (oral daily intake)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" lower_limit="62" upper_limit="66.4"/>
                    <measurement group_id="B2" value="59.0" lower_limit="51.5" upper_limit="70"/>
                    <measurement group_id="B3" value="66.8" lower_limit="63.1" upper_limit="70.4"/>
                    <measurement group_id="B4" value="63.4" lower_limit="62.7" upper_limit="67.7"/>
                    <measurement group_id="B5" value="62.2" lower_limit="59.5" upper_limit="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of Efavirenz</title>
        <description>MTD was determined by testing increasing doses up to 3000 mg (oral daily intake).&#xD;
The dose escalation scheme is the continual reassessment method likehood approach (CRML) described by O'Quigley and Shen [O'Quigley et al. Biometrics 1996].&#xD;
MTD reflects the highest dose of drug that did not cause a Dose-Limiting Toxicity (DLT) in &gt; 25% of participants.&#xD;
A DLT was any drug-related toxicity with grade ≥ 3 according to NCI-CTCAE v4.0 (except alopecia, nausea and vomiting, regardless of grade), any drug-related toxicity, regardless of grade, who led a treatment delay&gt; 14 days, a score ≥ 19 for the Hospital Anxiety And Depression Scale (HAD) during treatment.</description>
        <time_frame>Up to 28 days for each dosing cohort</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants who received at least 1 dose of Efavirenz, either at 600 mg, 1200 mg, 1800 mg, or 2200 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of Efavirenz</title>
          <description>MTD was determined by testing increasing doses up to 3000 mg (oral daily intake).&#xD;
The dose escalation scheme is the continual reassessment method likehood approach (CRML) described by O'Quigley and Shen [O'Quigley et al. Biometrics 1996].&#xD;
MTD reflects the highest dose of drug that did not cause a Dose-Limiting Toxicity (DLT) in &gt; 25% of participants.&#xD;
A DLT was any drug-related toxicity with grade ≥ 3 according to NCI-CTCAE v4.0 (except alopecia, nausea and vomiting, regardless of grade), any drug-related toxicity, regardless of grade, who led a treatment delay&gt; 14 days, a score ≥ 19 for the Hospital Anxiety And Depression Scale (HAD) during treatment.</description>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)</title>
        <description>A DLT was any drug-related toxicity with grade ≥ 3 according to NCI-CTCAE v4.0 (except alopecia, nausea and vomiting, regardless of grade), any drug-related toxicity, regardless of grade, who led a treatment delay&gt; 14 days, a score ≥ 19 for the Hospital Anxiety And Depression Scale (HAD) during treatment.</description>
        <time_frame>Up to 28 days for each dosing cohort</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Efavirenz: 600 mg</title>
            <description>Cohort 1 : Participants received 600 mg of Efavirenz (oral / once a day), until progression or toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz: 1200 mg</title>
            <description>Cohort 2 : Participants received 1200 mg of Efavirenz (oral / once a day), until progression or toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Efavirenz: 1800 mg</title>
            <description>Cohort 3 : Participants received 1800 mg of Efavirenz (oral / once a day), until progression or toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Efavirenz: 2200 mg</title>
            <description>Cohort 4 : Participants received 2200 mg of Efavirenz (oral / once a day), until progression or toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)</title>
          <description>A DLT was any drug-related toxicity with grade ≥ 3 according to NCI-CTCAE v4.0 (except alopecia, nausea and vomiting, regardless of grade), any drug-related toxicity, regardless of grade, who led a treatment delay&gt; 14 days, a score ≥ 19 for the Hospital Anxiety And Depression Scale (HAD) during treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-week Objective Response Rate</title>
        <description>Objective response is defined as complete or partial response (CR, PR) using the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Objective reponse rate is calculated as the number of patients with objective reponse divided by the number of alive patients.</description>
        <time_frame>up to 3 months after first adminitration of Efavirenz</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants who received at least 1 dose of Efavirenz, either at 600 mg, 1200 mg, 1800 mg, or 2200 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>12-week Objective Response Rate</title>
          <description>Objective response is defined as complete or partial response (CR, PR) using the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Objective reponse rate is calculated as the number of patients with objective reponse divided by the number of alive patients.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-week Non-progression Rate</title>
        <description>Non progression is defined as complete or partial response (CR, PR) or stable disease (SD), using the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Non-progression rate is calculated as the number of alive and progression free patients divided by the number of patients.</description>
        <time_frame>Evaluated up to 3 months after first administration of Efavirenz</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants who received at least 1 dose of Efavirenz, either at 600 mg, 1200 mg, 1800 mg, or 2200 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>12-week Non-progression Rate</title>
          <description>Non progression is defined as complete or partial response (CR, PR) or stable disease (SD), using the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Non-progression rate is calculated as the number of alive and progression free patients divided by the number of patients.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected until death or date of the end of study (6 months after the inclusion of the last patient)</time_frame>
      <desc>Adverse Events were monitored/assessed without regard to the specific Adverse Event Term.</desc>
      <group_list>
        <group group_id="E1">
          <title>Efavirenz: 600 mg</title>
          <description>Cohort 1 : Participants received 600 mg of Efavirenz (oral / once a day), until progression or toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Efavirenz: 1200 mg</title>
          <description>Cohort 2 : Participants received 1200 mg of Efavirenz (oral / once a day), until progression or toxicity.</description>
        </group>
        <group group_id="E3">
          <title>Efavirenz: 1800 mg</title>
          <description>Cohort 3 : Participants received 1800 mg of Efavirenz (oral / once a day), until progression or toxicity.</description>
        </group>
        <group group_id="E4">
          <title>Efavirenz: 2200 mg</title>
          <description>Cohort 4 : Participants received 2200 mg of Efavirenz (oral / once a day), until progression or toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Not collected</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Not collected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Not collected</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" events="7" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Not collected</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" events="9" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Not collected</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Not collected</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Not collected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Not collected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Not collected</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Not collected</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Not collected</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Not collected</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Not collected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" events="12" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Not collected</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Not collected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Not collected</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Guilhem Roubaud</name_or_title>
      <organization>Institut Bergonié</organization>
      <phone>33 5 56 33 33 33</phone>
      <email>g.roubaud@bordeaux.unicancer.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

